Vir Biotechnology

Share on: 

Vir is focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.  Vir Biotechnology will be partnering with Alnylam Pharmaceuticals to identify siRNA therapeutics to treat COVID-19. Vir Biotechnology has also identified two monoclonal antibodies that bind to SARS-CoV-2 and is working with WuXi Biologics to commercialize them. These antibodies target the spike (S) protein of the virus by entering through the cellular receptor ACE2.

San Francisco CA
United States